31.07.2021 | Correction
Correction to: Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan
Erschienen in: Advances in Therapy | Ausgabe 9/2021
Einloggen, um Zugang zu erhaltenExcerpt
In the original article, there were errors published. Please see correct versions of Tables 2, 3, 4, S2 and S3 below.
DTC
|
MTC
|
ATC
|
||||
---|---|---|---|---|---|---|
(n = 442)
|
(n = 28)
|
(n = 124)
|
||||
Initial dose per day
|
||||||
24 mg
|
337
|
(76.2)
|
22
|
(78.6)
|
87
|
(70.2)
|
20 mg
|
29
|
(6.6)
|
2
|
(7.1)
|
18
|
(14.5)
|
14 mg
|
29
|
(6.6)
|
0
|
(0.0)
|
9
|
(7.3)
|
10 mg
|
26
|
(5.9)
|
4
|
(14.3)
|
6
|
(4.8)
|
8 mg
|
15
|
(3.4)
|
0
|
(0.0)
|
2
|
(1.6)
|
4 mg
|
0
|
(0.0)
|
0
|
(0.0)
|
0
|
(0.0)
|
Othersa
|
6
|
(1.4)
|
0
|
(0.0)
|
2
|
(1.6)
|
Mean dose, mg/day, ± SDb
|
11.86
|
± 5.40
|
12.20
|
± 5.81
|
15.70
|
± 6.35
|
DTC (n = 442)
|
MTC (n = 28)
|
ATC (n = 124)
|
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Any ADR, n (%)
|
436
|
(98.6)
|
28
|
(100.0)
|
115
|
(92.7)
|
||||||
ADR, n (%)
|
Any grade
|
Grade ≥ 3
|
Any grade
|
Grade ≥ 3
|
Any grade
|
Grade ≥ 3
|
||||||
Hypertensiona
|
354
|
(80.1)
|
267
|
(60.4)
|
18
|
(64.3)
|
11
|
(39.3)
|
87
|
(70.2)
|
58
|
(46.8)
|
Proteinuria
|
192
|
(43.4)
|
76
|
(17.2)
|
11
|
(39.3)
|
4
|
(14.3)
|
37
|
(29.8)
|
9
|
(7.3)
|
Palmar-plantar erythrodysesthesia syndromeb
|
178
|
(40.3)
|
26
|
(5.9)
|
14
|
(50.0)
|
1
|
(3.6)
|
32
|
(25.8)
|
4
|
(3.2)
|
Decreased appetite
|
115
|
(26.0)
|
20
|
(4.5)
|
7
|
(25.0)
|
1
|
(3.6)
|
20
|
(16.1)
|
6
|
(4.8)
|
Platelet count decreased
|
97
|
(21.9)
|
20
|
(4.5)
|
4
|
(14.3)
|
1
|
(3.6)
|
28
|
(22.6)
|
16
|
(12.9)
|
Malaise
|
88
|
(19.9)
|
10
|
(2.3)
|
3
|
(10.7)
|
0
|
(0.0)
|
24
|
(19.4)
|
1
|
(0.8)
|
Diarrhea
|
85
|
(19.2)
|
17
|
(3.8)
|
8
|
(28.6)
|
3
|
(10.7)
|
15
|
(12.1)
|
1
|
(0.8)
|
DTC
|
MTC
|
ATC
|
||||
---|---|---|---|---|---|---|
N
|
442
|
–
|
28
|
–
|
124
|
–
|
Overall survival, days, median (95% CI)
|
–
|
–
|
101.0
|
(80.0–130.0)
|
||
12-month overall survival rate, % (95% CI)
|
75.7
|
(71.3–79.5)
|
83.0
|
(60.7–93.3)
|
15.6
|
(9.6–22.9)
|
Time-to-treatment failure, days, median (95% CI)
|
413.0
|
(375.0 to –)
|
405.0
|
(252.0–405.0)
|
74.5
|
(57.0–108.0)
|
12-month treatment continuation, % (95% CI)
|
57.0
|
(52.2–61.5)
|
57.1
|
(35.8–73.6)
|
9.4
|
(4.9–15.7)
|
N
|
368
|
–
|
20
|
–
|
105
|
–
|
Best overall responsea, n (%)
|
||||||
Complete response
|
10
|
(2.7)
|
1
|
(5.0)
|
3
|
(2.9)
|
Partial response
|
208
|
(56.5)
|
8
|
(40.0)
|
43
|
(41.0)
|
Stable disease
|
122
|
(33.2)
|
11
|
(55.0)
|
34
|
(32.4)
|
Progressive disease
|
25
|
(6.8)
|
0
|
(0.0)
|
25
|
(23.8)
|
Not evaluable
|
3
|
(0.8)
|
0
|
(0.0)
|
0
|
(0.0)
|
Overall response rateb, % (95% CI)
|
59.2
|
(54.03–64.30)
|
45.0
|
(23.06–68.47)
|
43.8
|
(34.14–53.83)
|
Disease control ratec, % (95% CI)
|
92.4
|
(89.19–94.88)
|
100.0
|
(83.16–100.00)
|
76.2
|
(66.89–83.96)
|